Playing the Devil’s Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? – ie Strategies to Revert Resistance to mTOR Inhibitors

In the last decade, the inhibition of the mechanistic target of Rapamycin (mTOR) in renal clear cell carcinoma (RCC) has disappointed the clinician’s expectations. Many clinical trials highlighted the low efficacy and unmanageable safety profile of first-generation mTOR inhibitors (Rapalogs), thus l...

Descripción completa

Detalles Bibliográficos
Autores principales: Pezzicoli, Gaetano, Filoni, Elisabetta, Gernone, Angela, Cosmai, Laura, Rizzo, Mimma, Porta, Camillo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500499/
https://www.ncbi.nlm.nih.gov/pubmed/34675658
http://dx.doi.org/10.2147/CMAR.S267220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500499/
https://www.ncbi.nlm.nih.gov/pubmed/34675658
http://dx.doi.org/10.2147/CMAR.S267220

Ejemplares similares